Difference between revisions of "Team:Northwestern/Description"
| Line 7: | Line 7: | ||
<style> | <style> | ||
p{padding-top: 10px; padding-right: 250px; padding-bottom: 10px; padding-left: 250px;} | p{padding-top: 10px; padding-right: 250px; padding-bottom: 10px; padding-left: 250px;} | ||
| − | |||
p{margin: 0; background-color: #f7f3ed;} | p{margin: 0; background-color: #f7f3ed;} | ||
figure {margin: 0; background-color: #f7f3ed;} | figure {margin: 0; background-color: #f7f3ed;} | ||
Revision as of 01:57, 13 September 2017
Inappropriate use of antibiotics has escalated the growing problem of antibiotic resistance in many threatening diseases. In 2014, the World Health Organization classified antibiotic resistance as a global epidemic. Inactivating resistance genes via Cas9 nuclease-mediated cleavage has been shown to be an effective means of combating this epidemic; however, methods of in vivo delivery are currently limited. Our team aims to deliver Cas9 to antibiotic-resistant, pathogenic bacteria through submicron bacterial outer membrane vesicles (OMVs) as a companion re-sensitization therapeutic to antibiotic treatment. OMVs are naturally produced by all Gram-negative bacteria and are used for crosstalk, stress responses, and nutrient acquisition. Their ability to be modified and directed with relative ease makes them an ideal carrier of CRISPR-Cas9. Aiding conventional antibiotic treatment, our technology will model a complete protein delivery system and transport functional Cas9 to target cells.
